Case Report
The patient who agreed to accept the organ was a 26-year-old male from Orissa, who had no potential voluntary kidney donor in his family and who was on regular hemodialysis for 15 months. He had experienced two life-threatening complications after being initiated on dialysis. He had difficult to control blood pressure despite adequate dialysis, multiple antihypertensives, and optimization of dry weight based on bioimpedance analysis using body composition monitor (Fresenius Medical care, Germany). He had developed intracerebral hemorrhage (ICH) requiring hospitalization 2 months earlier. Subsequently, after discharge from the hospital after treatment for the ICH, he developed pulmonary edema with respiratory failure requiring endotracheal intubation and intensive care unit admission. He was registered under the deceased donor kidney transplantation waiting list 9 months back. He held a graduate degree in business administration, and in the treatment team's assessment, he could take an informed decision on his treatment. In the interest of abundant caution, informed consent was obtained under video recording with all aspects about the transplantation with the kidney from a donor who was HBsAg positive, including the possibility of fulminant hepatic failure, explained to the patient and his father, in his mother tongue (Odia) by two members of the kidney transplantation team, whose mother tongue was also Odia. The patient was steadfast in his willingness to undergo transplantation with the kidney from the HBsAg-positive donor, and it was decided to proceed with organ harvesting and transplantation.
He had received four doses of hepatitis B vaccine; the last dose was 5 weeks earlier. His antibody titer (anti-HBs) checked 1 week earlier was protective (more than 10 IU/L - Table 2) . He was administered 600 IU of hepatitis B immunoglobulin before the transplantation operation and he was started on lamivudine prophylaxis. His serum samples were sent for HBsAg, anti-hepatitis B core antibody (HBcAb), and HBV DNA by Nucleic Acid Testing (NAT) just before the transplantation operation [ Table 2 ]. He was given induction with rabbit anti-thymoglobulin (3 mg/kg in two divided doses on D0 and D1) and was started on immunosuppression with tacrolimus, mycophenolate mofetil, and prednisolone. He had prompt diuresis on declamping.
Since there were no other potential recipients, the second kidney was discarded. After 1 year of follow-up, his liver function has remained normal. He was monitored for hepatitis B viremia every 3 months and he did not develop viremia for transplantation till now, 1 year after the transplantation.
discussion
The demand for organs far exceed availability in almost all countries. Efforts to expand the donor pool have explored different options, and accepting organs from donors with infections is one such strategy. [1] Transplantation from donors with active hepatitis C and HIV is increasingly being reported. According to the epidemiological classification of hepatitis B, India comes under the intermediate prevalence zone (2%-7%). [2] In endemic regions, the prevalence of anti-HBcAb-positive deceased donors may reach up to 24%. [3] Accepting such donors may allow expanding the donor pool, especially in areas endemic for HBV. The reported prevalence of HBsAg positivity in healthy blood donors in Tamil Nadu is 0.58%. [4] Of 98 potentially brain-dead patients reported to the deceased donor team at our center, 55 were tested for HBV infection, of whom 4 (7.2%) were found to be HBsAg positive (unpublished observation). The prevalence of occult HBV infection was found to be 4.71% among healthy blood donors at our center. [5] It is evident that considering potential donors with chronic HBV infection for organ harvesting, in situations where it can be undertaken safely, will allow a significant expansion of the donor pool.
It is pertinent to emphasize that accepting organs, including kidney, from a donor who is HBsAg positive is not usual practice and one need to exercise extreme caution if contemplating it. It is also important to understand that the risk of transmission of infection depends on the infection status of the donor as well as the immune status of the recipient, and both their status should be evaluated thoroughly before considering transplantation. The interpretation of the infection Tables 3 and 4 . [6] The Organ Procurement and Transplantation Network (OPTN), USA, recommends testing for HBsAg and anti-HBcAb in the potential deceased donor. [7] A living donor should undergo further testing including HBV DNA by the NAT. Transplantation of kidneys from anti-HBcAb-positive donors was associated with negligible de novo hepatitis B infection in the recipients compared to liver transplantation. [8, 9] However, there are reports of seroconversion after receiving the kidney from anti-HBcAb-positive donors, particularly when the recipient is anti-HBcAb or HBsAg negative. Among the anti-HBcAb-positive kidney recipients, 27% developed new anti-HBcAb and/or HBV surface antibody after transplant in one study. [10] A review by Mahboobi et al. [11] reported an overall seroconversion rate of 3.24% when transplanting organs from HBsAg-negative but anti-HBcAb-positive donors. None of these patients had clinical signs of hepatitis, higher mortality, or decreased graft survival.
Compared to HBsAg-negative/anti-HBc positive donors, HBsAg-positive donors are generally considered as associated with more risk of de novo infection. [12] Most of the centers used to consider transplant from HBsAg-positive donors to only matched HBsAg-positive recipients previously. The use of effective antiviral agents both as prophylaxis and as treatment along with hepatitis B immunoglobulin created more opportunities to receive the kidney from HBsAg-positive donors. Initial studies mentioned the use of hepatitis B immunoglobulin for the recipient at the time of transplant and [13, 14] The dose and duration of immunoglobulin and lamivudine varied in different studies. Table 5 describes different protocols used when recipients with nonprotective level of anti-HbS antibody received the kidney from donors with positive anti-HBc, and all of them had good outcomes.
Even though the need for prophylaxis is well recognized, especially in recipients with nonprotective antibody titers, there are no uniformly accepted protocols. The role of immunoglobulin and antiviral prophylaxis in recipients with protective titers of antibody is controversial. A recent study by Asuman Yavuz et al. from Turkey compared HBsAg-positive and negative donors in live renal transplantation. [19] In their study, 111 donors were HBsAg positive and 2057 were HBsAg negative; kidney transplantations were undertaken only if the recipient had hepatitis B antibody titer >10 mIU/mL and donor HBV DNA was negative. None of the patient received immunoglobulin or lamivudine. The study revealed no new HBV infections throughout the study period. Acute rejection rates, graft loss, and patient loss were similar between the two groups.
Jiang et al. [20] reported seven recipients, who received grafts from donors with hepatitis B viremia, whose mean HBV DNA level was 6.2 × 10 7 copies/mL. These patients were all positive for both anti-HBs and anti-HBc and received lamivudine and HBV immunoglobulin treatment. They were negative for HBsAg or HBV DNA at all follow-up visits and exhibited normal liver function to the end of follow-up. A significantly higher incidence of hepatitis (3 of 26 patients) was observed in recipients of kidneys from HBV DNA-positive donors on lamivudine prophylaxis, but none developed fulminant hepatitis, rejection, or graft loss. [21] It appears that renal transplantation from HBsAg-positive or anti-HBc-positive donors to recipients with a protective antibody is safe. A recent study suggests that the outcomes were similar whether the recipient received no prophylaxis, lamivudine alone, or lamivudine in combination with immunoglobulin. [22] Our case is unique, in that this is the first reported instance of kidney transplantation from an HBsAg-positive deceased donor from India. There were two earlier reports of kidney transplantation from HBsAg-positive donors, but both were living donors. [23, 24] Unlike deceased donor transplantation, living donor transplantation is an elective procedure and allows proper evaluation of the donor as well as recipients; treatment of the donor if necessary and preparation of the recipient in case, he was not vaccinated earlier or anti-HBsAb titers were not checked. Successful transplantation from a deceased donor is possible only if the center has a policy of vaccinating all patients in the deceased donor waiting list with hepatitis B vaccine as well as checking the anti-HBsAb titers.
conclusion
Transplantation of a kidney from a deceased donor with chronic HBV infection to a patient with protective levels of anti-HBs antibody titers did not result in the transmission of infection. Accepting donors with chronic HBV infection may be a safe option to expand the organ donor pool under appropriate circumstances.
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Table 5: Reported protocols for hepatitis B virus prophylaxis in transplant recipients Regimen
Chung et al. [15] 10,000 IU at transplant f/b either immunoglobulin every month for 12 months or lamivudine for 12 months Akalin et al. [16] One-year prophylaxis with lamivudine alone without immunoglobulin Veroux et al. [17] Single dose of 2000 IU immunoglobulin Ouseph et al. [18] Immunoglobulin or lamivudine which was suspended on follow-up if HBV DNA is not detectable HBV: Hepatitis B virus
